Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
about
RNA vaccines in cancer treatmentTranslatability scoring in drug development: eight case studiesCTLA-4 blockade: therapeutic potential in cancer treatmentsMelanoma immunotherapy dominates the fieldThe European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeuticsImmunotherapy for lung cancerTremelimumab: research and clinical developmentPredictive factors for immunotherapy in melanomaImmune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisStem cells and targeted approaches to melanoma cureImmune Checkpoint Blockade in Cancer TherapyPD-1 as an emerging therapeutic target in renal cell carcinoma: current evidenceCTLA-4 blockade in tumor models: an overview of preclinical and translational researchNew immunotherapies targeting the PD-1 pathwayThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentThe blockade of immune checkpoints in cancer immunotherapySafety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerBiologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanomaModulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanomaCTLA4 blockade broadens the peripheral T-cell receptor repertoireCytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.Inhibitors of B7-CD28 costimulation in urologic malignancies.Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyAntibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).Trends in cancer immunotherapyFocus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanomaIn situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II studyNovel anti-melanoma treatment: focus on immunotherapy.Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapyImmune checkpoint inhibitors in NSCLC.The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoringGM-CSF gene-modifed cancer cell immunotherapies: of mice and men.Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerationsClinical Development of Immune Checkpoint Inhibitors.Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.Targeting precision medicine toxicity: recent developments.Natural killer T cells in advanced melanoma patients treated with tremelimumab
P2860
Q21296852-BB783FC8-B155-435C-BBF4-C96C26914B46Q22241760-5F36CD9A-ED98-48A1-B217-9CC03B70B6CDQ24622666-82C086F7-EB38-4740-AF60-D55CBD47DAB7Q26738671-E8976A6C-2942-49C5-B155-A993C21FE2FAQ26738677-64E7E4AB-8317-4586-873C-7EA720DA72BEQ26751254-6678862C-9246-41A1-9003-5CE0C4519690Q26752822-66F5A44B-64C7-4BA2-9901-BD0EA34DC3ADQ26778765-F08A61A6-35BC-4CB8-BD86-1C8B9668C7AFQ26785746-81C62D40-04E3-4C45-9D9F-98439C4D2899Q26825014-547B5215-2EF0-4664-8F34-8A46F741033DQ26830509-6B7E1F4F-73ED-4B7B-9638-F1123B56DB64Q26865789-F647A985-8159-4236-B623-E0203D95FCEFQ26992295-276EF05B-0C9C-4C33-8894-1B795A34E0B5Q27010018-FDAE061A-3C78-467C-B584-2C302A89CF63Q27022789-DC020079-4DD6-4FCA-9536-CBF7CA323696Q27860852-4219D9B4-A372-4FEC-ABCB-93CB9DD273E7Q27860857-C9F8636D-AE42-4B35-816A-DF256B178704Q28307216-8523FEAA-718F-4E13-B6FC-040988830097Q28749278-2F3225F1-12E9-4DAE-8BA8-40902EBD2CADQ33560753-E5189538-FD9B-4C46-B6C4-9AB3981D8EC8Q33710973-10517B80-B344-4504-A33E-F80A73C797FBQ33827752-85FD132C-6A58-4482-9AA4-8BA2E755A609Q33880042-D4EB34E5-6C09-490C-BFE2-4530F9FF0F6BQ34000700-19A263AB-B27D-4989-888F-C3A0FEC67D64Q34052702-C9DE8972-AC8B-44EF-99AB-C5D0ADF62411Q34111789-46797828-B7A3-41DB-9994-B5C85A18BAB4Q34194680-2EB1707A-DA59-4259-AE61-378AB0487F4CQ34309404-6EA6AAD9-892A-4A96-BF77-F6F13ED8CE14Q34334598-4769E6B9-E44D-4544-B0F4-A4F7C014325CQ34437570-D9C1F13A-10D7-416D-A121-28BC7E963FE7Q34557531-0088968B-1FF0-4ACF-9455-4FD4823D448EQ34591128-57804572-44C6-483B-963B-7575C15DDC33Q34647109-922199EE-059E-453F-9272-DB9FA4645C88Q34658452-BCD93442-ADE3-46C0-9B70-BBC5C0D506E0Q34667662-4F56A7AE-E764-46C8-826B-2E8C1EBC252FQ34671498-7292B540-4053-471D-98F4-EEAEC93274DBQ34720087-99FED9A5-0AFA-4149-BC5B-5C436961B3FAQ35009889-59F947CB-9CCF-4C95-8FB7-454F116DAA1AQ35019470-3532B59F-055E-4562-AAB2-E2479A154886Q35027661-2AFE144A-12C8-4567-B7E6-F3BBBE51EC93
P2860
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Antitumor activity in melanoma ...... onoclonal antibody CP-675,206.
@en
Antitumor activity in melanoma ...... onoclonal antibody CP-675,206.
@nl
type
label
Antitumor activity in melanoma ...... onoclonal antibody CP-675,206.
@en
Antitumor activity in melanoma ...... onoclonal antibody CP-675,206.
@nl
prefLabel
Antitumor activity in melanoma ...... onoclonal antibody CP-675,206.
@en
Antitumor activity in melanoma ...... onoclonal antibody CP-675,206.
@nl
P2093
P921
P356
P1476
Antitumor activity in melanoma ...... onoclonal antibody CP-675,206.
@en
P2093
Amarnath Sharma
Antoni Ribas
Cecile A Bulanhagui
Charla A Parker
Dmitri Pavlov
Elisabeth Seja
Gabriel Lopez-Berestein
James M Reuben
Jesus Gomez-Navarro
John A Glaspy
P304
P356
10.1200/JCO.2005.01.109
P407
P577
2005-10-03T00:00:00Z